The Association Between COVID-19 and Invasive Pulmonary Aspergillosis: A Challenge for Health Care System

Ali Arianezhad1, Behnam Azizolahi2, Reza Ghaffariipour2

1 School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
2 Department of Medical Laboratory Sciences, School of Paramedicine, Dezful University of Medical Sciences, Dezful, Iran

Received: 01 Oct. 2021; Accepted: 18 May 2022

Abstract- The emerging disease of COVID-19 was announced as a pandemic in 2020, with wide prevalence worldwide. After the duration of the pandemic of the disease, reports based on the invasion of Aspergillus into patients' lungs with COVID-19 and their hospitalization in ICU were published by the researchers, which attracted the attention of other researchers to perform such studies. In this review, PubMed, ScienceDirect, Scopus, Springer, Wiley, ProQuest, Sid, Cochrane, and the search engine Google Scholar were searched for publications by the keywords include COVID-19, Aspergillus, SARS-CoV-2, Invasive pulmonary aspergillosis, fungal and viral co-infection or a combination of them. The data were extracted and descriptively discussed. Not many studies have been performed on the association between aspergillosis and COVID-19. However, although the results of the studies suggest some possible causes of these concomitant infections like underlying diseases and prolonged mechanical ventilation, they also recommend further studies. Since the diagnosis of common fungal and viral infections is difficult, the concurrent incidence of these two infections in patients becomes a therapeutic challenge. Accordingly, this issue increased the mortality rate in this group of patients, especially in those hospitalized in ICU. According to the recently performed studies, various problems, including underlying diseases and difficult diagnostic methods of some dangerous diseases like invasive aspergillosis, are discussed in patients with COVID-19. © 2022 Tehran University of Medical Sciences. All rights reserved. Acta Med Iran 2022;60(6):322-328.

Keywords: Immunosuppressive agents; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Glucocorticoids; Galactomannan; Co-infection

Introduction

Inhalation of fungal spores placed in the respiratory pathway is with induction or aggregation of respiratory diseases such as asthma, allergic rhinitis, sinusitis, and pneumonitis (1-4). Aspergillus is one of the fatal fungal species (5,6), which besides growing in respiratory pathways, has the ability to produce allergen. So, by fragmentation of fungal hyphae, it plays an important role in establishing allergic reactions (7,8) and annually threatens millions of humans' lives (9). Toxin secretion from fungi is another harmful process during fungal respiratory involvements. All these processes become more important when the patient develops immune system compromising, which can even lead to death (10).

In this regard, some reports indicated a high mortality rate in individuals with immune system weakness and with fungal pathogens, especially Aspergillus (11-13). Numerous studies have been done on immune response against fungal proliferation in airways and lungs, in which giant cells play a role as the first cells of the defense line against inhaled fungi (14). Accordingly, through this work, the resistance of the immune system increases against the invasion of inhaled fungi (15). Spores that are not phagocytosed and allowed to grow are responsible for performing allergic reactions (16,17).

Thereafter, the lymphatic immune system initiates to work, and in its glands, dendritic cells induce a specific immune pathway through both providing antigens to T lymphocyte cells and signaling produced by T-helper (18-
20). Other members of the immune system also play a role in the process of defeating fungal pathogens, including interleukin 1, interleukin 2, and interferon-gamma (21). Despite a clear role of the above-mentioned factors in inducing an allergic response to fungal pathogens, a distinct mechanism in this regard is not thoroughly identified yet (22-24). Besides genetic factors, environmental factors are also effective in the growth of fungal pathogens. So, it can be said that infection, lifestyle, elimination of normal flora of the respiratory system following the use of antibiotics, and change in dietary regimen can be effective in this process (25-27).

Previously, studies have been done on the incidence of invasive aspergillosis in patients with HIV, the results of which indicated the ability to defeat of immune system of the individual with HIV against the growth of Aspergillus fungi (28). Therefore, it can be said that each viral infection that has the ability of the body's immune system to weaken could inevitably provide an environment for the growth of opportunistic fungal pathogens like Aspergillus. Accordingly, one of these viral infections is COVID-19 (29). This virus was observed for the first time in Wuhan, China, in December 2019, and after spreading globally, it became a pandemic (30). Consequently, the World Health Organization introduced this virus as a health emergency internationally (31). Notably, this virus provides the environment for the growth of other infections by invading to respiratory system besides direct damaging the respiratory system by weakening the immune system. In addition, after the invasion of the virus into the respiratory system, in cytokine rate increases in tissue, which causes pulmonary fibrosis in patients with COVID-19 (32). Clinical symptoms of the disease of COVID-19 are fever, coughing, fatigue, myalgia, and in some cases, emerging gastrointestinal symptoms (33,34). In the pandemic of COVID-19, the invasion of Aspergillus fungi to patients’ lungs is considered a new challenge, which should be properly managed by health authorities (35,36). In the current review study, we investigated the prevalence and diagnostic methods of invasive pulmonary aspergillosis in patients with COVID-19.

Materials and Methods

In this review, PubMed, ScienceDirect, Scopus, Springer, Wiley, ProQuest, Sid, Cochrane, and the search engine Google Scholar were searched for publications by the keywords include COVID-19, Aspergillus, SARS-CoV-2, Invasive pulmonary aspergillosis, fungal and viral co-infection or a combination of them. In these searches, 441 articles were obtained, and after removing duplicate items and based on access to the full text of the articles, 255 articles were selected, which were first reviewed by title and then by abstract by two researchers in the fields of medical mycology and virology. Finally, the results of 21 articles that answered the question of this study were used directly in the present review.

Results

With the occurrence of the pandemic of SARS-CoV-2, a virus of the family Coronavirusidae, different studies have been done on the incidence of invasive aspergillosis in patients with COVID-19. Some previous studies have also been done on other diseases caused by other members of this viral family, such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The important point that Wang et al., has stated in their case study in 2003 was the invasion of Aspergillus to some tissues such as the brain, heart, adrenal glands, kidneys, and lung texture due to consuming high doses of methylprednisolone in 39-year-old patients with SARS. Correspondingly, this led to the patient's death (37).

Prattes et al., in a study in 2020, reported one case of concomitant infection of aspergillosis and COVID-19. The results of this study present the hypothesis of accompanying two diseases of COVID-19 and pulmonary aspergillosis and stated that this concomitant infection could consequently increase the mortality rate in patients (38).

This hypothesis was also stated by Blaize et al., in the assessment of another patient and stated that following an increase in virus proliferation, inflammatory and cytokine responses probably are the other factors of pulmonary invasion of Aspergillus (39).

In another study in 2020, Alanio et al., started research on 27 hospitalized patients with COVID-19 in ICU, which despite previous studies claiming consuming antiviral medication of oseltamivir as the reason for pulmonary aspergillosis involvement of patients with influenza, they did not use this medication in the treatment of these patients. In addition, according to a piece of advice by Chinese physicians recorded in previous studies, for all 27 patients, consuming corticosteroids was prescribed (to suppress inflammatory reactions). At the end of the research, due to a high dose of steroids, the incidence of pulmonary aspergillosis was observed in 33% of the studied patients (40).

Van Arkel et al., by considering their study population
COVID-19 and invasive pulmonary aspergillosis

consisting of 31 individuals (patients with two diseases of COVID-19 and pulmonary aspergillosis), stated that 19.4% (approximately high rate) of the patients had both viral and fungal infections (24).

Other studies stated similar rates, which can point to the prevalence rate of 33.3% (41) and 35.3% (42) of secondary fungal infections in ICU of hospitals in China.

Rutsaert et al., performed a study to investigate this association in 34 patients with COVID-19 with a mean age of 66 years old who were hospitalized in ICU. As a result, the invasion of Aspergillus was confirmed in four patients (43).

Another study aimed to discover the clinical characteristics of patients infected by two diseases of COVID-19 and pulmonary aspergillosis was performed by Wang et al., on 104 patients hospitalized in ICU. This study’s design was retrospective case series. Among all the patients, 8 patients (7.7%) were with invasive pulmonary aspergillosis, and all of them was a man with a mean age more than others. In addition, a diagnosis of pulmonary invasion of Aspergillus was made on average after almost 19 days, which is a long duration (44).

Four patterns of damage following the Aspergillus invasion of the lung in patients with COVID-19 were provided in 2020 by Filibeert et al., which consist of acute fibrinous with organizing pneumonia, diffuse alveolar damage, fibrosis, and organizing pneumonia (45).

Discussion

According to the results of the mentioned studies, different hypotheses have been stated about the causes of co-infection of invasive pulmonary aspergillosis and COVID-19. Also, different diagnostic methods for this fungal disease and the duration of its diagnosis have been discussed.

As previously mentioned about another member of the family, Coronaviridae, in the case study of Wang et al., consuming corticosteroids, although it was prescribed with the aim of resolving the symptoms of SARS disease, causes suppression of the immune system and provides the breeding environment for Aspergillus fungi (37).

In this regard, following the study of Blaize et al., the new point mentioned in their study was that since COVID-19 in some individuals rapidly leads to lung failure and death, in case of accompanying another deadly fungal disease such as aspergillosis, the mortality rate severely increases (39). Moreover, delay in the positivity of diagnostic indices of Aspergillus fungi (galactomannan index, beta- D glucan, microscopic evidence, and PCR) might be another reason for the increased mortality rate (39,46).

Although some laboratory tests such as galactomannan detection are considered the most sensitive diagnostic tests, since the health care team mostly attempts to perform such tests at the last stages of the disease (Sometimes this is due to the risk of disease transmission during sampling), they lose their opportunity for early diagnosis, which increases mortality rate (39,47,48). Therefore, it seems necessary to perform more studies with large sample sizes to design new protocols (48).

In addition, it is probable that symptoms of invasive pulmonary aspergillosis become emerge after two weeks of being infected with COVID-19 (38).

According to the previous cohort studies performed with the titles of accompanying two diseases of COVID-19 and aspergillosis, new results were achieved, and some of them confirmed previous studies. For instance, Verweij et al., in 2019, after the assessment of statistical data, found that despite using no immunosuppressants (The reason that was identified as the leading cause of providing a growth environment for Aspergillus), invasive pulmonary aspergillosis occurs in patients with COVID-19. In addition, due to the similarity of the images resulting from chest imaging of patients with COVID-19 and aspergillosis, it was difficult to distinguish between these two diseases in this way (49).

In some studies, like those performed by Gangeux et al., and Santana et al., some risk factors providing the environment for the invasion of fungal pathogens have been mentioned, including long-term hospitalization in ICU, development of acute respiratory failure syndrome, treatment with high doses of corticosteroids, the occurrence of cytokine storm in body, intubation, and long-term connection to the ventilator (23,50).

All the above-mentioned risk factors are observed in many cases of COVID-19 (33,34,51,52).

Therefore, most of the studies performed by Chinese physicians confirmed the claim that there is a statistical relationship between two diseases of COVID-19 and pulmonary aspergillosis (53,54).

There is no precise awareness of the effect of this fungal pathogen (Aspergillus) on the mortality rate of patients with influenza hospitalized in ICU in some studies yet (55,56).

However, according to another study, this background is available that the 90-day mortality rate in patients admitted to the ICU with viral influenza was 51% when accompanied by invasive pulmonary aspergillosis. In contrast, in patients with just influenza, the mortality rate was 28% (57).

Since following disease of COVID-19, almost most
symptomatic patients are hospitalized in ICU under the same conditions, which all were risk factors for infection by fungal-respiratory diseases, so it seems necessary to evaluate patients with COVID-19 regarding the involvement with opportunistic fungal pathogens, especially Aspergillus (23,58,59), as well, in case of any infection with fungal disease, process and way of treatment should be changed (60).

Wang et al., in their study, believed that well-timed diagnostic measures, including serology, graphy, and biopsy, should be done for early diagnosis of aspergillosis. Therefore, as it was observed, these diagnostic and therapeutic attempts decrease the number of critically ill patients compared to other research (44,57).

In addition, in some studies, a well-timed diagnosis of pulmonary aspergillosis in patients with COVID-19 has been stated as one of the challenges of treatment in this group of patients (58,61).

One of the main factors of mortality in patients whose immune system is suppressed is invasive aspergillosis (62), which definitely attacks to lungs (63), which is the organ targeted by COVID-19. Some laboratory methods of diagnosis of aspergillosis (such as culture, microscopic assessments, etc.), due to a long time of providing results as well as false-negative results (64,65), are unreliable. In contrast, the test of BAL-GM (which acts based on the presence of galactomannan as a diagnostic index) has a high sensitivity in the diagnosis of invasive aspergillosis (66). So some studies used this method for the final diagnosis of aspergillosis and in some cases to save the patients.

Cytokine storm, which is induced by the immune system against COVID-19, is one of the reasons for the incidence of symptoms of COVID-19 (51). Accordingly, the health care team uses glucocorticoids (GCs) to defeat this phenomenon in order to suppress the immune system. This attempt is known as an underlying factor for the growth of Aspergillus fungi in patients with COVID-19 in all studies cited in this research except just one article.

Given the above-mentioned problems regarding this issue, diagnosis of Aspergillus fungi and being invasive of the fungal pathogen make difficult the process of decision-making on appropriate diagnostic and therapeutic methods, especially while it is accompanied by a newly emerging disease such as COVID-19, which belongs to respiratory diseases and has a high fatality by itself.

Concomitant infection of these two diseases in one individual severely increases the mortality rate. Although huge information exists in this regard, and some methods are provided for diagnosis, definitely, there are many cases that are not diagnosed or not recorded. Accordingly, this can be due to a lack of the presence of therapeutic background to exposure to concomitant infection of these two diseases (COVID-19 and aspergillosis).

Finally, further studies are warranted with larger sample sizes in this regard, and making appropriate decisions in health and therapeutic policies considerably helps in decreasing the mortality rate caused by these two diseases.

References

1. Hogaboam CM, Carpenter KJ, Schuh JM, Buckland KF. Aspergillus and asthma--any link? Med Mycol 2005;43:S197-202.
2. Crameri R. Allergy and Asthma in Modern Society: A Scientific Approach. Basel: Karger Medical and Scientific Publishers; 2006.
3. Portnoy JM, Barnes CS, Kennedy K. Importance of mold allergy in asthma. Curr Allergy Asthma Rep 2008;8:71-8.
4. Kurup VP, Shen HD. Bananaee B. Respiratory fungal allergy. Microbes Infect 2000;2:1101-10.
5. Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev 2009;22:447-65.
6. Del Bono V, Mikulska M, Viscoli C. Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol 2008;15:586-93.
7. Göny RL, Reponen T, Willeke K, Schmechel D, Robine E, Boissier M, et al. Fungal fragments as indoor air biocontaminants. Appl Environ Microbiol 2002;68:3522-31.
8. Johannig E. Bioaerosols, fungi, bacteria, mycotoxins and human health: pathophysiology, clinical effects, exposure assessment, prevention and control in indoor environments and work. Albany (USA): Fungal Research Group Foundation; 2005.
9. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012;4:165rv113.
10. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011;11:275-88.
11. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007;67:1567-601.
12. Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol 2011;49:S7-12.
13. Reichenberger F, Habicht JM, Gratwohl A, Tamm M. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002;19:743-55.
14. Kauffman HF. Innate immune responses to environmental...
COVID-19 and invasive pulmonary aspergillosis

allergens. Clin Rev Allergy Immunol 2006;30:129-40.
15. Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc 2005;2:403-11.
16. Pylkkänen L, Gullstén H, Majuri ML, Andersson U, Vanhala E, Määttä J, et al. Exposure to Aspergillus fumigatus spores induces chemokine expression in mouse macrophages. Toxicology 2004;200:255-63.
17. Hohl TM, Van Epps HL, Rivera A, Morgan LA, Chen PL, Feldmesser M, et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 2005;1:e30.
18. Akbari O, DeKruyff RH, Umetu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2:725-31.
19. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006;6:476-83.
20. Spörrri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005;6:163-70.
21. Bozza S, Gaziano R, Spreca A, Bacci A, Montagnoli C, di Francesco P, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002;168:1362-70.
22. Salehi M, Ahmadakia K, Badali H, Khodavaisy S. Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran. Mycopathologia 2020;185:607-11.
23. Gangneux JP, Bougnoux ME, Damasou E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med 2020;30:100971.
24. van Arkel ALE, Ripstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med 2020;202:132-5.
25. Ober C, Thompson EE. Rethinking genetic models of asthma: the role of environmental modifiers. Curr Opin Immunol 2005;17:670-8.
26. von Mutius E. Allergies, infections and the hygiene hypothesis—the epidemiological evidence. Immunobiology 2007;212:433-9.
27. Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy 2005;35:1511-20.
28. Hakkouni AE, Mansouri N. Invasive pulmonary aspergillosis in a patient with human immunodeficiency virus (HIV). Pan Afr Med J 2018;31:40.
29. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia 2020;185:8-1.
30. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
31. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr 2020;10:537-40.
32. Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 2020;8:750-2.
33. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401-2.
34. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020;7:11.
35. Armstrong-James D, Youngs J, Bicanic T, Abdolrasouli A, Denning DW, Johnson E, et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J 2020;56:2002554.
36. Agrifoglio A, Cachafeiro L, Figueira JC, Añón JM, García de Lorenzo A. Critically ill patients with COVID-19 and candidaemia: We must keep this in mind. J Mycol Med 2020;30:101012.
37. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003;349:507-8.
38. Pratjes T, Valentin T, Hoenigl M, Talaric E, Reisinger AC, Eller P. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report. Med Mycol Case Rep 2021;31:2-5.
39. Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin AG, Thellier M, et al. Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. Emerg Infect Dis 2020;26:1636-7.
40. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 2020;8:e48-9.
41. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. Clin Infect Dis 2020;71:1937-42.
42. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care
3. Rutsaert L, Steinfeldt N, Van Hunsel T, Bomans P, Naesens R, Mertes H, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care 2020;10:71.

4. Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qi T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care 2020;24:299.

5. Flikweert AW, Grootenboers M, Yick DCY, du Mée AWF, van der Meer NJM, Rettig TCD, et al. Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series. J Crit Care 2020;59:149-55.

6. Gangneux JP, Rezine F, Guegan H, Pineaux K, Le Balch P, Prat E, et al. Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience. J Fungi (Basel) 2020;6:105.

7. Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J Fungi (Basel) 2020;6:91.

8. Lamoth F, Glampedakis E, Boilat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect 2020;26:1706-8.

9. Verweij PE, Gangneux JP, Bassetti M, Brüggemann RJM, Cornely OA, Koehler P, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe 2020;1:e53-5.

10. Santana MF, Pivoto G, Alexandre MAA, Baía-da-Silva DC, Borba M, Val FA, et al. Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. Rev Soc Bras Med Trop 2020;53:e20200401.

11. Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol 2020;92:2516-22.

12. Ronconi G, Tété G, Kritas SK, Gallenga CE, Caraffa A, Ross R, et al. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. J Biol Regul Homeost Agents 2020;34:767-73.

13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.

14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.

15. van de Veerdonk FL, Kolwijk E, Lestraad P, Hodiamont CJ, Rijnders BJ, van Paassen J, et al. Influenza-Associated Aspergillosis in Critically Ill Patients. Am J Respir Crit Care Med 2017;196:524-7.

16. Verweij PE, Brüggemann RJM, Wauters J, Rijnders BJA, Chiller T, van de Veerdonk FL. Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. Clin Infect Dis 2020;70:349-50.

17. Schauwvlieghe A, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018;6:782-92.

18. Mohamed A, Rogers TR, Talento AF. COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges. J Fungi (Basel) 2020;6:115.

19. Meijer EFJ, Döfferhoff ASM, Hoiting O, Buil JB, Meis JF. Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report. J Fungi (Basel) 2020;6:79.

20. Falces-Romero I, Ruiz-Bastían M, Díaz-Pollán B, Maseda E, García-Rodríguez J. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital. Mycoses 2020;63:1144-8.

21. Fekkar A, Poignon C, Blaize M, Lampros A. Fungal Infection during COVID-19: Does Aspergillus Mean Secondary Invasive Aspergillosis? Am J Respir Crit Care Med 2020;202:902-3.

22. Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008;121:e1286-94.

23. D’Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lamertijn L, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012;50:1258-63.

24. Francesco A, Kasiol Petrattiene R, Petrattis V, Kelaher AM, Schaufele R, et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 2006;44:2475-80.

25. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-22.

26. Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P, et al.
COVID-19 and invasive pulmonary aspergillosis

Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012;7:e43347.